亚洲国产超清无码专区,亚洲精品无码视频,美女亚洲一区

Lonoctocog alfa

NMR下載 COA and HPLC MSDS下載
names：
Lonoctocog alfa
CAS號：
1388129-63-2
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)
DBK502154-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK502154-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請垂詢
收藏商品商品點(diǎn)評加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	Lonoctocog alfa
英文別名	Lonoctocog alfa
CAS號	1388129-63-2
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性狀	NA
儲藏條件 Storage conditions

Lonoctocog alfa使用注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害。
3.取樣品的移液槍頭需及時(shí)更換，必要時(shí)為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時(shí)選用稱量紙，并無風(fēng)處取藥和稱量以免揚(yáng)撒，試劑的容器使用前務(wù)必確保干凈，并消毒。
5.取藥品時(shí)盡量采用多個藥勺分別使用，使用后清洗干凈。
6.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染。
大規(guī)格定制：定制產(chǎn)品請將信息發(fā)送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產(chǎn)品說明	The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body2. Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects2.There is further evidence that CBD also activates 5-HT1A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and μ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH)3,4.TargetActionsOrganismACannabinoid receptor 1Not AvailableHumansACannabinoid receptor 2Not AvailableHumansUG-protein coupled receptor 12inverse agonistHumansUGlycine receptor subunit alpha-1Not AvailableHumansUGlycine receptor (alpha-1/beta)Not AvailableHumansUGlycine receptor subunit alpha-3Not AvailableHumansUN-arachidonyl glycine receptorNot AvailableHumansUG-protein coupled receptor 55Not AvailableHumansU5-hydroxytryptamine receptor 1ANot AvailableHumansU5-hydroxytryptamine receptor 2ANot AvailableHumansUNeuronal acetylcholine receptor subunit alpha-7Not AvailableHumansUDelta-type opioid receptorNot AvailableHumansUMu-type opioid receptorNot AvailableHumansUPeroxisome proliferator-activated receptor gammaNot AvailableHumansUTransient receptor potential cation channel subfamily V member 1Not AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1GNot AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1HNot AvailableHumansUVoltage-dependent T-type calcium channel subunit alpha-1INot AvailableHumansUTransient receptor potential cation channel subfamily A member 1Not AvailableHumansUTransient receptor potential cation channel subfamily M member 8Not AvailableHumansUTransient receptor potential cation channel subfamily V member 2Not AvailableHumansUTransient receptor potential cation channel subfamily V member 3Not AvailableHumansUTransient receptor potential cation channel subfamily V member 4Not AvailableHumansUVoltage-dependent anion-selective channel protein 1Not AvailableHumansUProstaglandin G/H synthase 1inhibitorHumansUProstaglandin G/H synthase 2inhibitorHumansUAcetyl-CoA acetyltransferase, mitochondrialinhibitorHumansUSteroid 17-alpha-hydroxylase/17,20 lyaseinhibitorHumansU3-hydroxy-3-methylglutaryl-coenzyme A reductasestimulatorHumansUGlutathione reductase, mitochondrialstimulatorHumansUGlutathione peroxidase 1stimulatorHumansUIndoleamine 2,3-dioxygenase 1inhibitorHumansUArylalkylamine N-acetyltransferaseinhibitorHumansUCytochrome P450 1B1inhibitorHumansUCytochrome P450 3A5inhibitorHumansUCytochrome P450 2D6substrateinhibitorHumansUCytochrome P450 1A2inhibitorHumansUCytochrome P450 1A1inhibitorHumansUCytochrome P450 3A7inhibitorHumansUQuinone oxidoreductaseinhibitorHumansUCatalaseinhibitorHumansUFatty-acid amide hydrolase 1inhibitorinducerHumansUSuperoxide dismutase [Cu-Zn]inhibitorHumansUN-acylethanolamine-hydrolyzing acid amidaseinhibitorHumans
Introduction
Application1
Application2
Application3

警示圖
危險(xiǎn)性
危險(xiǎn)性警示	warning
安全聲明
安全防護(hù)
備注	實(shí)驗(yàn)過程中防止吸入、食如，做好安全防護(hù)